Introduction 53
A residual neuromuscular blockade is a practical problem in the field of clinical anaesthesia 54 and may lead to adverse clinical outcomes, such as increases in pulmonary complications in the 55 postoperative period, including pneumonia, atelectasis, hypoxemia and hypercapnia, which can 56 result in increased morbidity and mortality [1, 2] . Neuromuscular monitoring and the routine use 57 of reversal drugs are key factors in preventing postoperative residual neuromuscular blockades. 58 Sugammadex, which is a type of drug in a class of selective neuromuscular binding agents, 59 is a modified γ-cyclodextrin that encapsulates the neuromuscular blocking drug (rocuronium or 4 60 vecuronium) and results in the reversal of rocuronium-or vecuronium-induced neuromuscular 61 block [3, 4] . Sugammadex was developed as an alternative pharmacological drug that would be 62 capable of reversing neuromuscular blockades without the limitations that are presented by 63 anticholinesterase drugs. It was first introduced by the scientific community in 2002; since then, 64 both animal and human studies have demonstrated the efficacy and tolerability of this drug [5, 6] . 65 Additionally, from the time that this drug was introduced, several adverse events that are related 66 to the use of sugammadex, including coagulation disorders, have been reported [7] [8] [9] . In vitro 67 experiments have demonstrated that sugammadex influences the effects of factor Xa in the 68 coagulation pathway, which then leads to the inhibition of the prothrombine-to-thrombin 69 conversion [10]. Furthermore, it may inhibit the production of factor Xa via the intrinsic pathway 70 [10]. In human volunteers, it has been demonstrated that sugammadex at dosages of 4 mg/kg and 71 16 mg/kg resulted in moderate increases in prothrombin levels and activated partial thromboplastin 72 times [10]. However, the exact mechanism for these effects on coagulation are not fully 73 understood.
74
The aim of this study was to evaluate the effects of rocuronium, sugammadex and the 75 rocuronium-sugammadex complex on coagulation in rats. Experimental groups 87 In this study, the animals were randomly distributed into the following four groups (with 88 seven animals in each group): the Control group that did not receive any anaesthetic intervention; In all of the experimental groups, the rats were anaesthetized in a closed container with a 96 simultaneous flow of 2 L/min oxygen and 4% isoflurane during a time span of 5 -10 minutes until 97 the animals were unconscious. Thereafter, the trachea of each of the animals was intubated, and 6 98 anaesthesia was maintained with 1.5% -3% isoflurane in oxygen with a flow of 0.4 L/min. The following experimental sequences were conducted: 1 -solid food fasting for 2 hours 116 with free access to water; 2 -weighing the animal; 3 -induction of anaesthesia by using 4% 117 isoflurane in a closed container and spontaneous ventilation for 5 -10 minutes; 4 -tracheal 7 118 intubation; 5 -placement and fixation of the animals in a Claude Bernard device; 6 -mechanical 119 ventilation with a tidal volume of 8 ml/kg of oxygen and isoflurane in concentrations that were 120 sufficient to complete anaesthesia; 7 -dissection and cannulation of the left jugular vein for the 121 purpose of hydration (5 mL/kg/h of saline solution that was administered by the use of an infusion 122 pump [Anne manufacturer]); 8 -dissection and cannulation of the right carotid artery to monitor 123 the heart rate (HR) and the mean arterial pressure (MAP); 9 -waiting 10 minutes after the 124 preoperative preparation; 10 -measurements of haemodynamic and blood sampling parameters 
Results

153
The animals in the Rocuronium-Sugammadex group exhibited higher weights than the 154 animals in the other groups. However, the average weight remained within the predetermined 155 inclusion parameters (Table 1 ). There was a statistically significant difference between the Control 156 and Rocuronium-Sugammadex groups (p = 0.003).
95% Confidence Interval Groups
Mean SD Platelet counts were similar among the groups and between the sampling time points within 170 each group (Table 3) . Activated partial thromboplastin times (s) were similar among the groups and between the 182 sampling time points within each group (Table 5) . There was a statistically significant reduction in plasma fibrinogen levels between 188 sampling time points 1 and 2 in the Rocuronium-Sugammadex group (P = 0.035). There were no 189 statistically significant differences among the other groups (Table 6) .
171
190 The main finding of this study was a reduction in the plasma fibrinogen levels in the 197 Rocuronium-Sugammadex group.
198
In all of the groups that were examined, the weights of the animals were observed to be .
211
The present study demonstrated a reduction in plasma fibrinogen in the Rocuronium-
212
Sugammadex group. Although fibrinogen levels were reduced, they remained in the normal range, due to the saline replacement of the blood volume that was collected for laboratory testing [13] .
223
This may have led to a discrete haemodilution that may have promoted the reduction in fibrinogen 224 levels. Therefore, the reduction in fibrinogen levels could be due to the methodological parameters 225 of the study and not specifically because of the drugs that were examined.
226
The partial thromboplastin time corresponds to the time that it takes for the coagulation of 
